Benchmark helps deliver improved healthcare products and welfare services to the global aquaculture and livestock industries. Rising demand from clients for its products and services to manage sustainability practice and performance underlines BMK's opportunity for significant organic and external growth.
Streamlined for growth and efficiency
H1 2020 trading in Benchmark’s Genetics division was resilient in face of challenges posed by the pandemic, while in Advanced Nutrition recent difficulties were compounded by the shrimp sector’s exposure to the food service industry.
The ongoing restructuring and cost containment program, targeting £10m+ of annual savings, are being enacted under the guidance of a newly appointed aquaculture specialist as CEO.
Factoring in disposals and efficiencies, our new forecasts indicate liquidity remains well within its NOK bond-lending covenant terms. A key near term focus includes preparation for launch of BMK’s innovative sea lice treatment of CleanTreat® + BMK08, providing game-changing revenue prospects.
Our DCF valuation of BMK is £421m or 63 pence per share, using an 11% discount rate and 2.5% long-term growth - factoring in average Group revenue growth of 20% per annum 2021-25.Download Now Missing Out Get our research first
Interim Results Presentation
Peter George, Executive Chairman, Septima Maguire, CFO, and incoming CEO, Trond Williksen, present their Interim Results for the half year to the 31st March 2020, their focus on delivering true cash profitability across the group, and the progress they have made so far with their restructuring.